Back to Archived News
Stem Cell Therapeutics Announces Issuance of Additional Patent
Wednesday, September 26, 2007
SCT is granted intellectual property protection in Japan
Calgary, Alberta -- Stem Cell Therapeutics Corp. ("SCT")(TSX VENTURE: SSS) is pleased to announce that the Company's strong intellectual property portfolio has been enhanced by the addition of a patent granted in Japan.
This Japanese patent, numbered 3993560 and entitled "Combined Regulation of Neural Cell Production" protects a pharmaceutical composition for enhancing neuronal precursor cell formation in a variety of central nervous system (CNS) disorders including brain injury, stroke, Alzheimer's disease, Huntington's disease, and other CNS diseases. The strategy of using a therapeutic regimen of drugs to enhance neurogenesis, as taught in this patent, has the potential to be a key treatment for many CNS diseases.
SCT is currently in a Phase IIa clinical trial with its lead therapeutic regimen NTxTM-265, characterizing this approach as a strategy to treat stroke patients. By exploiting the capacity of endogenous adult neural stem cells to regenerate lost or dysfunctional brain tissue as a means of recovering lost motor, sensory or cognitive function, SCT is pursuing one of the most potent therapeutic strategies currently in clinical development.
"We are very pleased with the issuance of this patent in Japan as it not only extends our intellectual property coverage around the concept of a drug-based approach to regenerate brain tissue but also as its opens up additional clinical indications," said Dr. Alan Moore, President and CEO of Stem Cell Therapeutics. "This patent enhances our ability to pursue the use of Prolactin and Erythropoietin (EPO) for the treatment of significant CNS diseases, allowing us to widen our therapeutic scope initially focused on the development of a treatment for stroke using Human Chorionic Gonadotropin (hCG) and EPO. As such, we have already started to assess the efficacy of a Prolactin-EPO regimen in a pre-clinical model of Traumatic Brain Injury (TBI)."
About NTxTM-265: NTxTM-265 is an SCT developed therapeutic regimen of two drugs. It targets the treatment of stroke by repurposing two approved and clinically well-defined drugs. Human Chorionic Gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke. Animal studies have shown a significant recovery in motor function in animals that received the NTxTM-265 regimen after a stroke. SCT is currently enrolling patients in a phase IIa clinical trial in the United States and Canada in order to investigate the safety and efficacy of NTxTM-265 in humans.
About Stem Cell Therapeutics Corp.
Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Back to Archived News